Last Updated: Dec 27 2010 - Silobreaker


Fact Sheet for Mylan Incorporated

Nationality: United States
Contact Address: 1500 Corporate Drive  Canonsburg, PA 15317 United States Tel: +1 724-514-1800
General: Mylan Incorporated is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 140 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With approximately 15,500 employees, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service. The company ranks among the top five generics companies in several markets around the world and is the largest U.S.-based generics manufacturer in the world. Source: http://www.mylan.com/about_us/default.aspx
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First reported 10 hours ago - Updated 10 hours ago - 1 reports

FLUOXETINE (Fluoxetine Hydrochloride) Capsule [Mylan Pharmaceuticals Inc.]

First reported 21 hours ago - Updated 21 hours ago - 1 reports

Government approves 16 proposals of foreign direct investment amounting to about Rs 1646.875 crore

New Delhi: Based on the recommendations of Foreign Investment Promotion Board (FIPB) in its meeting held on May 10, 2013, the Central Government has approved sixteen (16) proposals of Foreign Direct Investment (FDI) amounting to Rs.1646.875crore appr ... [Published India Brand Equity Foundation - 21 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Mylan Inc prices USD1.15bn senior notes

Pharmaceutical company Mylan Inc (NasdaqGS:MYL) announced on Tuesday that it has priced its USD1.15bn senior notes. In a private placement, the company has priced its USD500m aggregate principal amount of 1.80% senior notes due 2016 at an issue price ... [Published Individual.com - 23 hours ago]
First reported Jun 19 2013 - Updated Jun 19 2013 - 1 reports

InSite Vision to join Merck & Pfizer to file patent infringement lawsuit against Mylan Pharma

InSite Vision Incorporated, a company advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite platform technologies, will be joining Merck, known as MSD outside the United States (US) and Canada, and Pfizer Inc. ... [Published PharmaBiz - Jun 19 2013]
First reported Jun 18 2013 - Updated Jun 18 2013 - 3 reports

Mylan Announces Pricing Of Senior Notes Due 2016 - Quick Facts

Mylan Inc. (MYL: Quote) announced the pricing of a private placement of $500 million aggregate principal amount of 1.80% Senior Notes due 2016 at an issue price of 99.925% and $650 million aggregate principal amount of 2.60% Senior Notes due 2018 at an ... [Published RTTNews.com - Jun 18 2013]
First reported Jun 18 2013 - Updated Jun 19 2013 - 1 reports

FIPB clears 16 FDI proposals

The government also approved Korea Western Power Coâs proposal to invest in an Indian company to the tune of Rs 270 crore. According to reports, the Government has approved 16 projects envisaging foreign investment worth Rs 16.47bn.The board, headed by ... [Published India Infoline - Jun 18 2013]
First reported Jun 18 2013 - Updated Jun 18 2013 - 2 reports

InSite Vision to jointly file patent infringement lawsuit against Mylan Pharmaceuticals along with Merck

InSite Vision Incorporated (OTC:INSV), a company focussed on advancing new ophthalmologic products for unmet eye care needs, announced on Monday that it will be joining Merck (NYSE:MRK)(MSD outside the US and Canada) and Pfizer Inc (NYSE:PFE) in filing ... [Published Individual.com - Jun 18 2013]
First reported Jun 18 2013 - Updated Jun 18 2013 - 3 reports

Mylan’s NZ unit profit soars as sales growth outpaces costs

Mylan New Zealand, the local unit of the world's third-largest generic-drug maker, boosted profit by two-thirds last year as sales growth outpaced expenses.Profit rose 62 percent to $9.4 million in the 12 months ended December 31, the Auckland-based company ... [Published National Business Review - Jun 18 2013]
First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Label Expansion for Astellas Drug Zacks

Astellas Pharma Inc. (ALPMY) recently announced the approval of Prograf in Japan for an additional indication.Prograf is now approved for interstitial pneumonia associated with polymyositis/dermatomyositis.$ It was granted orphan drug status by the Ministry ... [Published Yahoo! Finance - Jun 17 2013]
First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Mylan Presents at the Goldman Sachs 34th Annual Global Healthcare Conference

Mylan Inc., a generic and specialty pharmaceutical company, has announced that Executive Chairman Robert Coury and CFO John Sheehan presented at the Goldman Sachs 34th Annual Global Healthcare Conference on June 12 at the Terranea Resort, Rancho Palos ... [Published Individual.com - Jun 17 2013]
First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Form 4 MYLAN INC. For: Jun 14 Filed by: BRESCH HEATHER M

StreetInsider.com - Form 4 MYLAN INC. For: Jun 14 Filed by: BRESCH HEATHER M ... [Published Street Insider - Jun 14 2013]
Entities: Mylan Incorporated
First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

OXYBUTYNIN CHLORIDE Tablet, Extended Release [Mylan Pharmaceuticals Inc.]

In Focus
Network
Network

Blogs

sort by: Date | Relevance
TOLBUTAMIDEtablet [Mylan Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - May 15 2013]
Updated Date: May 15, 2013 EST ...
LEVALBUTEROLsolution [Mylan Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 19 2013]
Updated Date: Mar 19, 2013 EST ...
Does Mylan Have Upside Potential? [Published Wall St. Cheat Sheet - Apr 17 2013]
With shares of Mylan ( NASDAQ:MYL ) trading at around $27.85, is MYL an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : C = Catalyst for the Stock’s Movement Mylan ...
ZOLMITRIPTANtablet, Film Coated [Mylan Pharmace... [Published DailyMed Drug Label Updates for the last seven ... - May 15 2013]
Updated Date: May 15, 2013 EST ...
Do Fundamentals Favor Mylan? [Published Wall St. Cheat Sheet - Mar 11 2013]
With shares of Mylan ( NASDAQ:MYL ) trading at around $30.73, is MYL an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : C = Catalyst for the Stock’s Movement Numbers ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Mylan Launches Generic Tricor® Tablets [Published PR Newswire: Policy & Public Interest - May 17 2013]
Mylan Schedules First Quarter 2013 Financial Re... [Published PR Newswire: Health - Apr 09 2013]
Mylan Launches Generic Antara® Capsules [Published PR Newswire: Health - Feb 25 2013]
Mylan Schedules Fourth Quarter and Year End 201... [Published PR Newswire: Health - Feb 13 2013]
Mylan Announces Fortamet® Settlement Agreement [Published PR Newswire: Health - Mar 13 2013]
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.